{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:37:50Z","timestamp":1770835070103,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Les Amis de L'Institut Bordet","award":["Grant 2016-02"],"award-info":[{"award-number":["Grant 2016-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10549-017-4628-3","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T21:37:52Z","timestamp":1514324272000},"page":"631-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)"],"prefix":"10.1007","volume":"168","author":[{"given":"Noam","family":"Ponde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Ameels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Zardavas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Di Cosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Bozovic-Spasojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Maetens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Berghorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Ruiz","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar-Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Rodeheffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"4628_CR1","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v8\u2013v30. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdv298","journal-title":"Ann Oncol"},{"key":"4628_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdw544","volume":"28","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, Costa A, Senkus E et al (2016) 3rd ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 28:16\u201333. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdw544","journal-title":"Ann Oncol."},{"key":"4628_CR3","doi-asserted-by":"crossref","first-page":"e000073","DOI":"10.1136\/esmoopen-2016-000073","volume":"1","author":"N Pond\u00e9","year":"2016","unstructured":"Pond\u00e9 N, Lambertini M, De Azambuja E (2016) Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 1:e000073","journal-title":"ESMO Open"},{"key":"4628_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.breast.2014.04.002","volume":"23","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Pinto AC et al (2014) Cardiotoxicity of systemic agents used in breast cancer. Breast Edinb Scotl 23:317\u2013328. \n                        https:\/\/doi.org\/10.1016\/j.breast.2014.04.002","journal-title":"Breast Edinb Scotl"},{"key":"4628_CR5","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8\u00a0years of median follow-up in the herceptin Adjuvant trial (BIG 1-01). J Clin Oncol Off J Am Soc Clin Oncol 32:2159\u20132165. \n                        https:\/\/doi.org\/10.1200\/JCO.2013.53.9288","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4628_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124\u20131130. \n                        https:\/\/doi.org\/10.1200\/JCO.2008.21.4437","journal-title":"J Clin Oncol"},{"key":"4628_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl 379:633\u2013640. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(11)61847-3","journal-title":"Lancet Lond Engl"},{"key":"4628_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M et al (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15:1137\u20131146. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(14)70320-1","journal-title":"Lancet Oncol"},{"key":"4628_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J et al (2016) Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol Off J Am Soc Clin Oncol 34:1034\u20131042. \n                        https:\/\/doi.org\/10.1200\/JCO.2015.62.1797","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4628_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso F, Costa A, Norton L et al (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871\u20131888. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdu385","journal-title":"Ann Oncol"},{"key":"4628_CR11","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743. \n                        https:\/\/doi.org\/10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"key":"4628_CR12","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538\u20135546. \n                        https:\/\/doi.org\/10.1200\/JCO.2009.23.3734","journal-title":"J Clin Oncol"},{"key":"4628_CR13","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529\u20135537. \n                        https:\/\/doi.org\/10.1200\/JCO.2008.20.6847","journal-title":"J Clin Oncol"},{"key":"4628_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783\u2013792. \n                        https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"4628_CR15","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. \n                        https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"4628_CR16","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 23:vii155\u2013vii166. \n                        https:\/\/doi.org\/10.1093\/annonc\/mds293","journal-title":"Ann Oncol"},{"key":"4628_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","volume":"13","author":"T Eschenhagen","year":"2011","unstructured":"Eschenhagen T, Force T, Ewer MS et al (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13:1\u201310. \n                        https:\/\/doi.org\/10.1093\/eurjhf\/hfq213","journal-title":"Eur J Heart Fail"},{"key":"4628_CR18","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","volume":"113","author":"RS Vasan","year":"2006","unstructured":"Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113:2335\u20132362. \n                        https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.482570","journal-title":"Circulation"},{"key":"4628_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200. \n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"4628_CR20","unstructured":"Breast. pdf. (2016) \n                        https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n                        \n                    . Accessed 3 Nov 2016"},{"key":"4628_CR21","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801. \n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"4628_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.03.016","author":"R Witteles","year":"2016","unstructured":"Witteles R (2016) Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. \n                        https:\/\/doi.org\/10.1016\/j.cardfail.2016.03.016","journal-title":"J Card Fail"},{"key":"4628_CR23","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol Off J Am Soc Clin Oncol 28:3910\u20133916. \n                        https:\/\/doi.org\/10.1200\/JCO.2009.27.3615","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4628_CR24","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/JCO.2009.26.5900","volume":"28","author":"C Dang","year":"2010","unstructured":"Dang C, Lin N, Moy B et al (2010) Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2\/neu-overexpressed\/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 28:2982\u20132988. \n                        https:\/\/doi.org\/10.1200\/JCO.2009.26.5900","journal-title":"J Clin Oncol"},{"key":"4628_CR25","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","volume":"17","author":"PG Morris","year":"2011","unstructured":"Morris PG, Chen C, Steingart R et al (2011) Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res Off J Am Assoc Cancer Res 17:3490\u20133499. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1359","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"4628_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12282-014-0520-8","volume":"22","author":"S Mokuyasu","year":"2015","unstructured":"Mokuyasu S, Suzuki Y, Kawahara E et al (2015) High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer. Breast Cancer 22:563\u2013569. \n                        https:\/\/doi.org\/10.1007\/s12282-014-0520-8","journal-title":"Breast Cancer"},{"key":"4628_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B et al (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53:105\u2013113. \n                        https:\/\/doi.org\/10.1016\/j.pcad.2010.06.007","journal-title":"Prog Cardiovasc Dis"},{"key":"4628_CR28","doi-asserted-by":"publisher","first-page":"12268","DOI":"10.3390\/ijms131012268","volume":"13","author":"A-S Hervent","year":"2012","unstructured":"Hervent A-S, De Keulenaer GW (2012) Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci 13:12268\u201312286. \n                        https:\/\/doi.org\/10.3390\/ijms131012268","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4628_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/jco.2015.65.7916","volume":"35","author":"D Zardavas","year":"2016","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ et al (2016) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35(8):878\u2013884. \n                        https:\/\/doi.org\/10.1200\/jco.2015.65.7916","journal-title":"J Clin Oncol"},{"key":"4628_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63:809\u2013816. \n                        https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061","journal-title":"J Am Coll Cardiol"},{"key":"4628_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","volume":"21","author":"AF Yu","year":"2016","unstructured":"Yu AF, Manrique C, Pun S et al (2016) Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer. Oncologist 21:418\u2013424. \n                        https:\/\/doi.org\/10.1634\/theoncologist.2015-0321","journal-title":"Oncologist"},{"key":"4628_CR32","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"N Fallah-Rad","year":"2011","unstructured":"Fallah-Rad N, Walker JR, Wassef A et al (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57:2263\u20132270. \n                        https:\/\/doi.org\/10.1016\/j.jacc.2010.11.063","journal-title":"J Am Coll Cardiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4628-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T05:58:59Z","timestamp":1520402339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4628"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4628-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}